Site Navigation
General Information
Category: biotechnology & health
BSA 06-09: Glycosylated Carborane Metalloporphyrins
BNL Reference Number: BSA 06-09
Patent Status: Application Number 20080279781 was published on November 13, 2008
Summary
Structure of glycosyl-carboranylporphyrin.
Glycosyl-modified carboranyl porphyrin compounds have improved solubility, providing enhanced formulation and targeting opportunities for these therapeutic and diagnostic compounds.
Description
The invention provides low toxicity boronated compounds and their use in the diagnosis, visualization and treatment of tumors.
Benefits
The glycosylation of the carborane porphyrin compounds provides enhanced solubility and potential tumor targeting specificity while reducing lipophilic behavior for use of the compound in tumor treatment particularly in boron neutron capture therapy (BNCT).
Applications and Industries
These compounds can be used in BNCT, a cancer treatment and Photodynamic Therapy (PDT). These porphyrin compounds can be used as These compounds can be used in BNCT, a cancer treatment and PDT. These porphyrin compounds can be used as MRI, SPECT, and PET imaging diagnostic and treatment-monitoring reagents when complexed to suitable metal ions.
Have Questions?
For more information about this technology, contact Christine Brakel, (631) 344-7134.
